MRK vs DGX
By Alex · Tickerpine
Merck & Company, Inc. vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | DGX |
|---|---|---|
| Price | $132.92 | $237.77 |
| Market cap | $327.94B | $26.24B |
| P/E ratio | 106.3 | 25.2 |
| ROE | 6.96% | 14.60% |
| Profit margin | 4.77% | 9.19% |
| Revenue growth | 5.10% | 10.20% |
| Dividend yield | 2.56% | 1.45% |
| Beta | 0.21 | 0.55 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs DGX in plain English
- MRK is the bigger company — about 12.5× the market cap of DGX.
- DGX is cheaper on earnings (P/E 25.2 vs 106.3).
- DGX earns a higher return on equity (15% vs 7%).
- DGX is growing revenue faster (10% vs 5%).
- MRK has the higher dividend yield (2.56% vs 1.45%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Company, Inc. would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.